Recent Investment Analysts’ Ratings Changes for Doximity (DOCS)

Doximity (NASDAQ: DOCS) has recently received a number of price target changes and ratings updates:

• 11/21/2024 – Doximity had its price target raised by analysts at JPMorgan Chase & Co. from $30.00 to $48.00. They now have a “neutral” rating on the stock.
• 11/15/2024 – Doximity is now covered by analysts at The Goldman Sachs Group, Inc.. They set a “neutral” rating and a $58.00 price target on the stock.
• 11/14/2024 – Doximity had its price target raised by analysts at Truist Financial Co. from $35.00 to $49.00. They now have a “hold” rating on the stock.
• 11/14/2024 – Doximity was upgraded by analysts at Morgan Stanley from an “underweight” rating to an “equal weight” rating. They now have a $53.00 price target on the stock, up previously from $33.00.
• 11/13/2024 – Doximity had its “hold” rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $60.00 price target on the stock, up previously from $40.00.
• 11/13/2024 – Doximity was downgraded by analysts at Canaccord Genuity Group Inc. from a “buy” rating to a “hold” rating. They now have a $60.00 price target on the stock, up previously from $40.00.
• 11/11/2024 – Doximity had its price target raised by analysts at Barclays PLC from $52.00 to $75.00. They now have an “overweight” rating on the stock.
• 11/8/2024 – Doximity was upgraded by analysts at KeyCorp from a “sector weight” rating to an “overweight” rating. They now have a $70.00 price target on the stock.
• 11/8/2024 – Doximity had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $65.00 price target on the stock, up previously from $37.00.
• 11/8/2024 – Doximity was upgraded by analysts at Wells Fargo & Company from an “underweight” rating to an “equal weight” rating. They now have a $41.00 price target on the stock, up previously from $19.00.
• 10/30/2024 – Doximity had its price target raised by analysts at Morgan Stanley from $26.00 to $33.00. They now have an “underweight” rating on the stock.
• 10/15/2024 – Doximity was upgraded by analysts at Barclays PLC from an “equal weight” rating to an “overweight” rating. They now have a $52.00 price target on the stock, up previously from $35.00.
• 10/8/2024 – Doximity had its price target raised by analysts at Evercore ISI from $34.00 to $45.00. They now have an “in-line” rating on the stock.
• 10/7/2024 – Doximity had its price target raised by analysts at Bank of America Co. from $32.00 to $45.00. They now have a “neutral” rating on the stock.

Doximity Trading Down 3.8 %

DOCS stock opened at $48.00 on Friday. The firm has a market cap of $8.96 billion, a P/E ratio of 55.17, a P/E/G ratio of 4.18 and a beta of 1.30. The stock’s 50 day simple moving average is $44.47 and its 200 day simple moving average is $34.84. Doximity, Inc. has a 12-month low of $22.96 and a 12-month high of $61.75.

Institutional Trading of Doximity

A number of institutional investors and hedge funds have recently modified their holdings of DOCS. LRI Investments LLC bought a new stake in shares of Doximity during the 1st quarter valued at about $27,000. Farther Finance Advisors LLC boosted its stake in Doximity by 324.2% in the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock valued at $34,000 after acquiring an additional 603 shares during the period. Blue Trust Inc. grew its holdings in shares of Doximity by 621.4% during the second quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock valued at $37,000 after purchasing an additional 1,193 shares during the last quarter. Quarry LP raised its position in shares of Doximity by 101.2% during the 2nd quarter. Quarry LP now owns 1,616 shares of the company’s stock worth $45,000 after purchasing an additional 131,253 shares during the period. Finally, DekaBank Deutsche Girozentrale bought a new stake in shares of Doximity in the 1st quarter worth approximately $46,000. 87.19% of the stock is owned by institutional investors and hedge funds.

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.